Phase II Study of E7389 Administered as an IV Bolus Infusion Day 1 and Day 8 Every 3 Weeks in Pre-Treated Patients With Advanced and/or Metastatic Soft Tissue Sarcoma.
Phase of Trial: Phase II
Latest Information Update: 24 Mar 2017
At a glance
- Drugs Eribulin (Primary)
- Indications Haemangiosarcoma; Leiomyosarcoma; Liposarcoma; Rhabdomyosarcoma; Sarcoma; Soft tissue sarcoma; Synovial sarcoma
- Focus Therapeutic Use
- Sponsors Eisai Inc
- 31 Aug 2018 Biomarkers information updated
- 24 May 2016 According to Eisai media release, data of this trial will be presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO), in June 2016.
- 23 Apr 2014 Status changed from discontinued to completed as reported by ClinicalTrials.gov